Scottsdale diagnostics company licenses biomarker technologies developed at ASU Biodesign with support from AzTE

SCOTTSDALE, Arizona, October 25, 2013 – Provista Diagnostics, Inc., a leading molecular diagnostics company focused on developing and commercializing proprietary diagnostic, prognostic and predictive tests for cancers affecting women, has licensed a series of biomarker technologies developed by researchers at the Biodesign Institute of Arizona State University. Provista will evaluate the technologies for use in the early detection of breast cancer, ovarian cancer and HPV.